On March 6, 2023 Phanes Therapeutics, Inc., a clinical stage biotech company focused on innovative drug discovery and development in oncology, reported that it has entered into a research collaboration with Xyphos Biosciences, Inc. an Astellas Company (Press release, Phanes Therapeutics, MAR 6, 2023, View Source [SID1234628218]). The collaboration will leverage Phanes’ proprietary technology platforms, PACbody and SPECpair, in the evaluation of cell therapies in oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Phanes will receive a technology access payment and further collaborative research support. The details of the financial terms were not disclosed.

"We are delighted to have the opportunity to collaborate with Xyphos," said Dr. Ming Wang CEO of Phanes. "PACbody and SPECpair allow construction of native IgG-like bispecific antibodies and production of the molecules using the conventional manufacturing process for monoclonal antibodies. The lead molecule Phanes made using these technologies has entered Phase 1 clinical study. With the bispecific antibody technology platforms we have built, Phanes is well positioned to make important impacts in cell therapies."